Heparin (GAG-hed) inhibits LCR activity of human papillomavirus type 18 by decreasing AP1 binding.
about
Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical CancerSelective interaction of heparin with the variable region 3 within surface glycoprotein of laboratory-adapted feline immunodeficiency virusThe Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System.
P2860
Heparin (GAG-hed) inhibits LCR activity of human papillomavirus type 18 by decreasing AP1 binding.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Heparin (GAG-hed) inhibits LCR ...... 18 by decreasing AP1 binding.
@ast
Heparin (GAG-hed) inhibits LCR ...... 18 by decreasing AP1 binding.
@en
Heparin
@nl
type
label
Heparin (GAG-hed) inhibits LCR ...... 18 by decreasing AP1 binding.
@ast
Heparin (GAG-hed) inhibits LCR ...... 18 by decreasing AP1 binding.
@en
Heparin
@nl
prefLabel
Heparin (GAG-hed) inhibits LCR ...... 18 by decreasing AP1 binding.
@ast
Heparin (GAG-hed) inhibits LCR ...... 18 by decreasing AP1 binding.
@en
Heparin
@nl
P2093
P2860
P356
P1433
P1476
Heparin (GAG-hed) inhibits LCR ...... 18 by decreasing AP1 binding.
@en
P2093
Alejandro García-Carrancá
Enrique García-Villa
Esther López-Bayghen
Irma Castelán-Sánchez
Néstor Morales-Peza
Patricio Gariglio
Rita Villanueva
Rocio Tapia
P2860
P2888
P356
10.1186/1471-2407-6-218
P407
P577
2006-08-31T00:00:00Z
P5875
P6179
1051822018